Precision Medicine in Graves’ Disease: CD40 Gene Variants Predict Clinical Response to an Anti-CD40 Monoclonal Antibody

BACKGROUND: CD40, a key co-stimulatory molecule expressed on antigen-presenting cells, is genetically associated with a number of autoimmune diseases including Graves’ disease (GD). Therefore, recent therapies targeting CD40 have been developed, including the anti-CD40 monoclonal antibody Iscalimab....

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Front Endocrinol (Lausanne)
Päätekijät: Faustino, Larissa C., Kahaly, George J., Frommer, Lara, Concepcion, Erlinda, Stefan-Lifshitz, Mihaela, Tomer, Yaron
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Frontiers Media S.A. 2021
Aiheet:
Endocrinology
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC8212124/
https://ncbi.nlm.nih.gov/pubmed/34149627
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fendo.2021.691781
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia